REGULATORY · COMPETITIVE · USA
FTC Reaches Proposed Settlement With CVS Caremark
Change
The Federal Trade Commission reached a proposed settlement with CVS Caremark over allegations that its pharmacy benefit manager inflated insulin prices and impeded access to the diabetes treatment.
Why it matters
The FTC filed a document indicating a proposed settlement with CVS Caremark resolving allegations that the company's PBM inflated insulin prices and impeded access. The proposed agreement is subject to review and approval by the FTC chair. CVS has said final terms are pending and expects the settlement process to conclude in the coming weeks. The matter follows a final settlement last month between the FTC and another large PBM, Express Scripts, and originates from an FTC complaint filed in September 2024 against multiple PBMs.
Implications
- · Raises settlement exposure tied to the liability finding
- · Adds a compliance obligation for affected operators
Who is affected
- · Insurers
- · Legal teams
What to watch
- · FTC chair review and approval of the proposed settlement
- · Settlement finalization timing (CVS expects conclusion in the coming weeks)
Source
Topics
Law & Public Safety Regulatory Actions Compliance Health & Medicine Pharma & Biotech